BLIS is characterized by high expression of the VEGF signature, which is associated with tumor angiogenesis and poor prognosis.18 In patients with the BLIS subtype without BRCA germline mutation in arm E, we assessed the effect of anti-VEGF/VEGFR therapy. The gene discussed is KDR; the disease is neoplasm.